Molecular diagnostics is the method used to analyze biological markers in the genome and proteome. The technology of molecular diagnostic is primarily used in infectious diseases, blood screening, histology, oncology, prenatal, coagulation, tissue typing, inherited diseases, genetic testing, and pharmacogenomics segments. With the help of such techniques various diseases such as cardiovascular diseases (CVD), diabetes, and respiratory disorders can be monitored or diagnosed. Innovation in this technology will also help physicians in providing proper treatment therapy to the patients.

Molecular Diagnostics Market Dynamics
Growing prevalence of chronic disease increased usage of biomarkers and high demand for personalized medicines and technology advancements are the major drivers of the molecular diagnostics market. According to the World Health Organization, by 2020, chronic diseases are estimated to account for around 58% of the global burden of disease and 60% of this burden will occur in emerging countries. The governments are keen on controlling and preventing these diseases by putting greater emphasis on preventive health solutions and personalized care. Various advancements in precise detection and diagnoses of disease will help reduce the cost of treating these chronic conditions. Molecular diagnostics technique leads to the development of advanced diagnostics and blood screening platforms and tests. It also helps to develop a better understanding of the nature of chronic diseases and devise pathways to develop personalized treatments. Therefore, the molecular diagnostics market is set to increase exponentially in the future. The regulatory landscape and reimbursement issue are the major restraints for the global molecular diagnostics market. Molecular diagnostics in cancer management and pharmacogenomics are the major opportunities for this market. The shift in technology such as point of care will further boost this market.
Table of Content
1. MARKET OVERVIEW
1.1. Market Definition
1.2. Research Methodology
1.3. Market Segmentation
2. EXECUTIVE SUMMARY
3. MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities
3.4. Trends
4. INDUSTRY ANALYSIS
4.1. Value Chain Analysis
4.2. Technology Roadmap
4.3. Regulatory Issues
5. MOLECULAR DIAGNOSTICS MARKET, BY PRODUCTS
5.1. Segment Share
5.2. Products
5.2.1. Instruments And Systems
5.2.2. Reagents And Consumables
6. MOLECULAR DIAGNOSTICS MARKET, BY APPLICATIONS
6.1. Segment Share
6.2. By Applications
6.2.1. Infectious Diseases
6.2.2. Blood Screening
6.2.3. Histology
6.2.4. Oncology
6.2.5. Prenatal
6.2.6. Coagulation
6.2.7. Tissue Typing
6.2.8. Inherited Diseases
6.2.9. Genetic Testing And
6.2.10. Pharmacogenomics
7. MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGIES
7.1. Segment Share
7.2. By Technologies
7.2.1. DNA Sequencing
7.2.2. PCR Microarray
7.2.3. Fluorescent In Situ Hybridization
7.2.4. Other Technologies
8. MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1. North America
8.1.1. By Country
8.1.1.1. U.S.
8.1.1.2. Rest of North America
8.1.2. By Products
8.1.3. By Applications
8.1.4. By Technologies
8.2. Europe
8.2.1. By Country
8.2.1.1. France
8.2.1.2. Germany
8.2.1.3. U.K
8.2.1.4. Rest of Europe
8.2.2. By Products
8.2.3. By Applications
8.2.4. By Technologies
8.3. Asia-Pacific
8.3.1. By Country
8.3.1.1. China
8.3.1.2. India
8.3.1.3. Japan
8.3.1.4. Rest of Asia-Pacific
8.3.2. By Products
8.3.3. By Applications
8.3.4. By Technologies
8.4. Rest of the World (RoW)
8.4.1. By Country
8.4.1.1. Latin America
8.4.1.2. Middle East and Africa
8.4.2. By Products
8.4.3. By Applications
8.4.4. By Technologies
9. COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Key Innovator Companies
10. KEY MARKET PLAYERS
10.1. Abbott Laboratories
10.1.1. Overview
10.1.2. Key Strategies
10.1.3. Recent Developments
10.2. Becton, Dickinson and Company
10.2.1. Overview
10.2.2. Key Strategies
10.2.3. Recent Developments
10.3. Cepheid Inc
10.3.1. Overview
10.3.2. Key Strategies
10.3.3. Recent Developments
10.4. Grifols International, S.A.
10.4.1. Overview
10.4.2. Key Strategies
10.4.3. Recent Developments
10.5. Hologic, Inc.
10.5.1. Overview
10.5.2. Key Strategies
10.5.3. Recent Developments
10.6. QIAGEN, Inc.
10.6.1. Overview
10.6.2. Key Strategies
10.6.3. Recent Developments
10.7. F. Hoffmann-La Roche Ltd.
10.7.1. Overview
10.7.2. Key Strategies
10.7.3. Recent Developments
10.8. Siemens AG
10.8.1. Overview
10.8.2. Key Strategies
10.8.3. Recent Developments
11. SCALAR 360 DEGREE MARKET PERSPECTIVE
12. APPENDIX